If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Hideya Ohnishi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles
Neoplasms Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Dendritic Cells Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Monocytes Medicine & Life Sciences
Regulatory T-Lymphocytes Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2019

  • 1578 Citations
  • 24 h-Index
  • 82 Article
  • 8 Review article
  • 1 Chapter
  • 1 Comment/debate

Liprin-α4 as a new therapeutic target for SCLC as an upstream mediator of HIF1α

Onishi, H., Yamasaki, A., Nakamura, K., Ichimiya, S., Yanai, K., Umebayashi, M., Nagai, S. & Morisaki, T., Mar 1 2019, In : Anticancer research. 39, 3, p. 1179-1184 6 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Cell Hypoxia
CD45 Antigens
Hypoxia-Inducible Factor 1
3 Citations (Scopus)

Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma

Nakamura, S., Sadakari, Y., Ohtsuka, T., Okayama, T., Nakashima, Y., Gotoh, Y., Saeki, K., Mori, Y., Nakata, K., Miyasaka, Y., Onishi, H., Oda, Y., Goggins, M. & Nakamura, M., Jul 15 2019, In : Annals of Surgical Oncology. 26, 7, p. 2104-2111 8 p.

Research output: Contribution to journalArticle

Pancreatic Juice

Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy

Oyama, Y., Onishi, H., Koga, S., Murahashi, M., Ichimiya, S., Nakayama, K., Fujimura, A., Kawamoto, M., Imaizumi, A., Umebayashi, M., Ohuchida, K., Morisaki, T. & Nakamura, M., Jan 1 2019, (Accepted/In press) In : Journal of Immunotherapy.

Research output: Contribution to journalArticle

Pancreatic Neoplasms

PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor

Fujimura, A., Nakayama, K., Imaizumi, A., Kawamoto, M., Oyama, Y., Ichimiya, S., Umebayashi, M., Koya, N., Morisaki, T., Nakagawa, T. & Onishi, H., Oct 1 2019, In : Cancer Immunology, Immunotherapy. 68, 10, p. 1649-1660 12 p.

Research output: Contribution to journalArticle

Non-Receptor Type 3 Protein Tyrosine Phosphatase
Extracellular Signal-Regulated MAP Kinases
1 Citation (Scopus)

Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines

Kubo, M., Umebayashi, M., Kurata, K., Mori, H., Kai, M., Onishi, H., Katano, M., Nakamura, M. & Morisaki, T., Jul 2018, In : Anticancer research. 38, 7, p. 4273-4279 7 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Cell Line
Breast Neoplasms
Bispecific Antibodies